LLS says third COVID-19 shot can boost antibody levels in blood cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Leukemia & Lymphoma Society published a study showing that more than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine, despite having no detectable antibodies after the first two doses. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login